This risk for ketoacidosis can be simply mitigated by not using SGLT2 inhibitors in individuals with type 1 diabetes and ensuring that insulin doses are not omitted in insulin-treated patients with T2D. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.